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ABSTRACT
Introduction: Biologic therapies have
improved the clinical management of
ankylosing spondylitis (AS). Few head-to-head
studies have directly compared the efficacy of
these agents. This study was conducted to
indirectly compare the efficacy of biologic
agents for treatment of active AS.
Methods: A targeted literature review was
conducted to identify randomized clinical
trials for adalimumab, infliximab, golimumab,
certolizumab pegol, etanercept, and
secukinumab for the treatment of active AS.
The clinical efficacy was evaluated using
ASAS20 and ASAS40 and synthesized via a
Bayesian network meta-analysis. Number
needed to treat (NNT) was calculated as the
reciprocal of incremental response rate of each
biologic versus placebo. Comparisons were also
made in terms of cost per incremental ASAS20
or ASAS40 responder.
Results: Fifteen studies were identified, which
included ASAS20 and/or ASAS40 response rates
at Week 12 to Week 16. Patients with AS treated
with infliximab had the lowest NNT for ASAS20
of 2.3, followed by those treated with
adalimumab (2.8) and etanercept (2.9).
Adalimumab had the lowest 12-week cost per
additional ASAS20 responder at $26,888,
followed by infliximab at $28,175 and
golimumab at $28,199. Patients treated with
infliximab also had the lowest NNT for ASAS40
(2.6), followed by those treated with
adalimumab (2.8) and secukinumab (3.5).
Adalimumab had the lowest cost per
additional ASAS40 responder at $26,898,
followed by infliximab at $32,508 and
etanercept at $34,406.
Conclusion: Infliximab had the lowest NNT to
achieve an additional ASAS20/40 response, and
adalimumab had the lowest cost per ASAS20/40
responder among biologic agents for the
treatment of active AS.
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INTRODUCTION
Ankylosing spondylitis (AS), a type of
spondyloarthritis, is a chronic systemic
rheumatic inflammatory disease of the axial
skeleton, large peripheral joints, and entheses
[1]. The principal feature of AS is inflammation
of the sacroiliac joint at the base of the spine
followed by rising inflammation along the
spine, resulting in back pain and stiffness [2].
The standard of care for AS includes drugs such
as non-steroidal anti-inflammatory drugs
(NSAIDs), disease-modifying anti-rheumatic
drugs (DMARDs), and non-drug interventions
such as physical therapy. Although these drugs
may offer palliation of symptoms, including
spinal pain, peripheral joint pain, and physical
function [1, 3], none has been shown to alter
the progression of AS.
AS is associated with significant direct
medical costs in terms of medication,
outpatient visits, hospitalizations, and
alternative treatments [4]. In addition, given
the progressive nature of AS and the related loss
of functional ability, it leads to an increase in
work disability and loss of productivity,
particularly for individuals who undertake
manual work [5]. Hence, AS is associated with
a significant economic burden on both patients
and society [3, 6]. Effective treatment
interventions can reduce the severity of the
disease and increase patients’ physical function
and overall quality of life, while also improving
work capacity and productivity [7].
Targeted biologic therapies have
revolutionized the clinical management of AS.
Currently, five different tumor necrosis factor
(TNF)-a inhibitors including adalimumab,
certolizumab pegol, etanercept, golimumab,
and infliximab are approved for the treatment
of active AS (an infliximab biosimilar has also
been approved, but is not currently marketed in
the US). Secukinumab, an interleukin-17
inhibitor, was recently approved by the Food
and Drug Administration (FDA) for the
treatment of active AS [8]. Clinical trials have
shown that these agents produce clinically
important benefits to patients by improving
physical functioning and reducing disease
activity [9–13]. A previous meta-analysis
synthesized data of different agents and
concluded that TNF-a blockers improve disease
activity and functional capacity for AS [14].
However, few head-to-head studies have
directly compared the efficacy of these agents,
and the comparative effectiveness among
different biologic agents for AS treatment,
especially for newer agents such as
certolizumab pegol and secukinumab, is not
well understood. Reliable evidence about the
comparative effectiveness of these therapies is
important to inform clinical and economic
decisions regarding their use.
To fill these gaps, indirect comparisons of
treatment outcomes across separate randomized
trials can be used to provide valuable
comparative evidence. Network meta-analysis
is an approach that synthesizes information
from several randomized comparisons to deliver
internally consistent estimates of the treatment
effects among competing interventions, while
maintaining the randomization within each
trial [15, 16]. Detailed methodological reviews
and implementation guidelines for network
meta-analyses have been published
[15, 17–19], and network meta-analyses have
become a preferred source of comparative
evidence for researchers, health-care decision
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makers, and health technology assessment
agencies [15, 20, 21].
The objective of this study was to determine
the relative efficacy of the six approved biologic
agents for active AS using a network
meta-analysis, and to evaluate the incremental




Phase III randomized clinical trials of TNF-a
inhibitors (i.e., adalimumab, certolizumab
pegol, etanercept, golimumab, and infliximab)
and interleukin-17 inhibitors (i.e.,
secukinumab) for active AS were identified
from a targeted literature review (January 1,
2000 to July 20, 2015). Trials were required to
have been conducted among adult patients
with active AS (defined as fulfilling the
modified New York criteria for AS) [22].
Patients with non-radiographic axial
spondylitis were excluded from this study. In
addition, trials were required to be either
placebo-controlled or a head-to-head
comparison of two of the approved biologic
agents. Trials were also required to have
reported assessments in ankylosing spondylitis
20% response (ASAS20) and/or 40% response
(ASAS40) at Week 12–16. Trial arms were
required to use dose(s) approved by the FDA
(e.g., adalimumab 40 mg every other week,
golimumab 50 mg every month, and
infliximab 5 mg/kg at 0, 2 and 6 weeks, then
every 6 weeks). For certolizumab pegol and
etanercept, which have two approved dosing
schedules (certolizumab pegol 400 mg at week
0, 2, and 4 followed by either 200 mg every
other week or 400 mg every 4 weeks, and
etanercept 25 mg twice weekly or etanercept
50 mg once weekly, respectively), these dosing
schedules were assumed to be equivalent
therapeutic doses and analyzed jointly in the
analysis. For secukinumab, two approved
dosing schedules were included in this study—
one with a loading dosage (150 mg at Weeks 0,
1, 2, 3, 4, and every 4 weeks thereafter) and one
without a loading dosage (150 mg every
4 weeks). Secukinumab efficacy was evaluated
collectively using the schedule with the loading
dosage (the schedule with the loading dosage
was examined during the double-blind
placebo-controlled period in clinical trials,
while the schedule without a loading dosage
was evaluated among cross-over placebo
patients), and costs were evaluated separately
for the two secukinumab dosing schedules.
The study selection process was performed
by two independent researchers with
disagreements resolved by a third researcher.
Data abstraction was performed by two
independent researchers using a standardized
data abstraction form.
Efficacy Measures
The ASAS criteria, the primary outcome in most
AS trials, was used to define response [23].
ASAS20 is defined as an improvement of 20%
(and absolute improvement of 10 units) in three
of the four domains (patient global assessment,
pain, function, and inflammation), and absence
of deterioration in the potential remaining
domain. ASAS40 is defined similarly with a
required improvement of 40%. The Committee
for Medicinal Products for Human use (CHMP)
has noted that the higher improvement of
ASAS40 may be a more appropriate endpoint
to evaluate biologic therapies [24], and ASAS40
may be associated with clinical meaningful
improvements in health-related quality of life
[25]. For the purpose of analysis, outcomes were
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evaluated at week 12 (when week 12 outcomes
were not available, outcomes reported at week
14 or week 16 were substituted for the week 12
outcomes).
Costs
This study was conducted from a US payer
perspective, and only biologic drug acquisition
costs and associated administration costs were
considered in the analysis. Unit drug costs as of
July 20, 2015 were based on the US wholesale
acquisition cost (WAC) obtained from
ReadyPrice [26]. Based on the dosing
schedules, unit costs, and administration costs,
12-week costs for each agent were calculated.
The drug cost of infliximab was based on an
80-kg adult. Administration cost (intravenous
infusion) for infliximab in the US as of July 20,
2015 was obtained from US Department of
Health and Human Services (CPT code 96,413
for the initial hour and 96,415 for subsequent
hours [27]). Infusion of infliximab was assumed
to take 4 h [27, 28].
Statistical Methods
A network meta-analysis was conducted to assess
the comparative efficacy of the six approved
biologic agents for the treatment of active AS.
The networkmeta-analysis was conductedwithin
a Bayesian approach, as this approach can deliver
both statistical estimations and a framework for
probabilistic decision-making under uncertainty
[16].Using a randomeffectsmodel, thenumberof
people achieving anASAS20 (or ASAS40) response
at Week 12–16 was assumed to follow a binomial
likelihood, with the corresponding probabilities
being related to the treatment effects via a logit
link function. Assessment of the goodness-of-fit
and model diagnostics was based on the residual
deviance and the deviance information criterion.
Non-informative priors were applied to ensure
that treatment comparisons were driven by the
observeddata.Estimatedcomparativeeffectswere
summarized using posterior medians and 95%
credible intervals (CrI). Numbers needed to treat
(NNT) for each additional ASAS20 or ASAS40
responder were calculated as the reciprocal of the
response rate difference between the agent and
placebo. The incremental cost per responder for
each treatment was calculated as the product of
the 12-week costs and the NNT. Given that the
efficacymeasures from the clinical trials are based
on intent-to-treat (ITT) analysis, the incremental
costs per responder calculated in this study are
also based on the ITT population. All analyses
were conducted using Bayesian Markov chain
MonteCarlo (MCMC)withOpenBUGS 3.2.3 [16].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
The targeted literature review identified 15 trials
that met the inclusion criteria and reported
ASAS20 and/or ASAS40 response rates from
Week 12 to Week 16 after initiation of
treatment (Table 1). Fourteen trials were
placebo-controlled and one trial directly
compared etanercept and infliximab [29].
Among the 14 placebo-controlled trials,
adalimumab was investigated in 3 trials
[9, 30, 31], certolizumab pegol in 1 trial [10],
etanercept in 4 trials [11, 32–34], golimumab in
2 trials [12, 35], infliximab in 2 trials [13, 36],
and secukinumab in 2 trials [37]. Figure 1 shows
the evidence network of this study. All trials
included were considered high quality, in terms
326 Rheumatol Ther (2016) 3:323–336
Table 1 Summary of results from trials included in the network meta-analysis
Trial name Treatment N ASAS20 at Week 12 ASAS40 at Week 12
N % N %
ATLAS [9] Placebo 107 22 20.6 14 13.1
Adalimumab 40 mg 208 121 58.2 83 39.9
M03-606 [30] Placebo 44 12 27.3 4 9.1
Adalimumab 40 mg 38 18 47.4 17 44.7
Huang [31] Placebo 115 35 30.4 11 9.6
Adalimumab 40 mg 229 154 67.2 102 44.5
RAPID-axSpA [10] Placebo 57 21 36.8 11 19.3
Certolizumab 200 mg 65 37 56.9 26 40.0
Certolizumab 400 mg 56 36 64.3 28 50.0
Calin [32] Placebo 39 9 23.1 – –
Etanercept 25 mg 45 27 60.0 – –
Gorman [33]a Placebo 20 7 35.0 – –
Etanercept 25 mg 20 15 75.0 – –
Enbrel AS Study [11] Placebo 139 39 28.1 – –
Etanercept 25 mg 138 82 59.4 – –
Etanercept Study 314 [34] Placebo 51 19 37.3 11 21.6
Etanercept 25 mg 150 107 71.3 80 53.3
Etanercept 50 mg 155 115 74.2 90 58.1
Giardina [29] Etanercept 50 mg 25 15 60.0 11 43.0
Inﬂiximab 5 mg/kg 25 19 75.0 14 55.0
Bao [12]b Placebo 105 26 24.8 10 9.6
Golimumab 50 mg 108 53 49.1 29 26.9
GO-RAISE [35]c Placebo 78 17 21.8 12 15.5
Golimumab 50 mg 138 82 59.4 62 44.9
ASSERT [13] Placebo 78 16 20.5 10 12.8
Inﬂiximab 5 mg/kg 201 124 61.9 99 49.3
Braun [36] Placebo 35 10 27.2 – –
Inﬂiximab 5 mg/kg 35 24 68.8 – –
MEASURE 1 [37]d Placebo 122 35 28.7 16 13.1
Secukinumab 75 mg 124 74 59.7 41 33.1
Secukinumab 150 mg 125 76 60.8 52 41.6
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of randomization, blinding, sample size,
appropriate analysis, and data presentation,
with the exception of the one open-label trial
with a small sample size [29]. The majority of
trials reported ASAS20 and/or ASAS40 at Week
12, with the exception of the golimumab trial
which reported ASAS20 and ASAS40 at Week 14,
and the secukinumab trials which reported
ASAS20 and ASAS40 at Week 16. The majority
of trials were multi-center with the exception of
two studies in China [12, 31], one study in Italy
[30], one study in Canada [30], and one study in
California, US [33]. In addition to fulfilling the
modified New York criteria, the majority of
trials required patients to have a Bath
Ankylosing Spondylitis Disease Activity Index
(BASDAI) greater than or equal to 4, a spinal
pain assessment score or a back pain score
greater than or equal to 4 (on a 10-point visual
analog scale or a 10-point numerical rating
scale), and inadequate response to one or more
NSAIDs. The certolizumab pegol and
secukinumab trials enrolled patients with prior
anti-TNF agent exposure (20% in the
RAPID-axSpA trial [10], 27% in the MEASURE




Trial name Treatment N ASAS20 at Week 12 ASAS40 at Week 12
N % N %
MEASURE 2 [37]d Placebo 74 21 28.4 8 10.8
Secukinumab 75 mg 73 30 41.1 19 26.0
Secukinumab 150 mg 72 44 61.1 26 36.1
a In this study, ASAS20 response was deﬁned as 20 % or greater improvement in at least three of ﬁve outcome measures
(duration of morning stiffness, degree of nocturnal spinal pain, the Bath Ankylosing Spondylitis Functional Index, the
patient’s global assessment of disease activity, and the score for joint swelling)
b ASAS20 responses were assessed at week 14
c Efﬁcacy outcomes were assessed at week 14
d Efﬁcacy outcomes were assessed at week 16
Fig. 1 Evidence network of biologic agents for treatment of active AS. A total of 15 phase III trials for active AS were
identiﬁed through a targeted literature review and were included in the network. AS ankylosing spondylitis
328 Rheumatol Ther (2016) 3:323–336
NCT01649375, respectively), whereas all other
agents were assessed in TNF-naı¨ve populations.
Network Meta-Analysis: ASAS20
Patients with AS treated with infliximab had the
highest probability of achieving ASAS20 (71.7%;
95% CrI 59.5–82.0%) and the lowest NNT of 2.3
(95% CrI 1.9–3.1), followed by those treated with
adalimumab (ASAS20, 63.6%; NNT, 2.8),
etanercept (ASAS20, 62.0%; NNT, 2.9),
secukinumab (ASAS20, 60.3%; NNT, 4.0),
golimumab (ASAS20, 60.2%; NNT, 3.1), and
certolizumab pegol (ASAS20, 50.5%; NNT, 4.4).
Infliximab had a probability of 76% of having the
highest ASAS20 response among all comparators,
followed by adalimumab with a 9% probability,
and golimumab with a 5% probability (Fig. 2a).
Incorporating the cost component, adalimumab
had the lowest 12-week cost per additional
ASAS20 responder at $26,888 (95% CrI
$21,720–$37,320), followed by infliximab at
$28,175 ($22,903–$38,694), etanercept at
$28,199 ($22,483–$38,633), golimumab at
$30,417 ($22,550–$49,510), secukinumab
without a loading dosage at $33,847
($25,149–$53,293), certolizumab pegol at
$60,326 ($33,593–$232,542), and secukinumab
with a loading dosage at $67,694
($50,299–$106,586). Adalimumab had a
probability of 38% of having the lowest cost per
ASAS20 responder among all comparators,
followed by etanercept with a 22% probability,
infliximab with a 21% probability, and
golimumab with a 14% probability (Fig. 2b).
Detailed results of the network meta-analysis of
ASAS20 for all agents are shown in Table 2.
Network Meta-Analysis: ASAS40
Patients with AS treated with infliximab had the
highest probability of achieving ASAS40 (51.5%;
95% CrI 33.4–70.0%) and the lowest NNT of 2.6
(95% CrI 1.8–4.9), followed by adalimumab
(ASAS40, 49.2%; NNT, 2.8), secukinumab
(ASAS40, 42.4%; NNT, 3.5), etanercept
(ASAS40, 41.4%; NNT, 3.6), golimumab
(ASAS40, 38.6%; NNT, 4.0), and certolizumab
pegol (ASAS40, 34.8%; NNT, 4.7). Infliximab
had a probability of 48% of having the highest
ASAS40 response among all comparators,
followed by adalimumab with a probability of
29%, secukinumab with a 9% probability, and
etanercept with a 6% probability. Incorporating
the cost component, adalimumab had the
lowest 12-week cost per additional ASAS40
responder at $26,898 (95% CrI
$19,483–$41,699), followed by infliximab at
$32,508 ($21,954–$60,308), etanercept at
$34,406 ($20,866–$76,436), secukinumab
without a loading dosage at $37,850
($24,274–$72,096), golimumab at $39,030
($23,760–$83,570), certolizumab pegol at
$64,051 ($31,815–$227,020), and secukinumab
with a loading dosage at $75,701
($48,547–$144,191). Adalimumab had a
probability of 56% of having the lowest cost
per ASAS40 responder among all comparators,
followed by infliximab with a 17% probability,
etanercept with a 14% probability,
secukinumab without a loading dosage with a
7% probability, and golimumab with a 6%
probability. Detailed results of the network
meta-analysis of ASAS40 for all agents are
shown in Table 3.
DISCUSSION
The primary goal of AS treatment is to relieve
symptoms, maintain physical function, and
prevent complications [1]. The assessment in
ankylosing spondylitis (ASAS) group
recommended that physical function, spinal
pain, patient global assessment, and
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Fig. 2 Ranking probabilities of biologic agents for treatment of active ankylosing spondylitis. a Ranking probabilities in
ASAS20 response. b Ranking probabilities in cost per ASAS20 responder
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inflammation to be the core set of criteria to
evaluate AS treatment response, and used them
to construct composite criteria for use in AS
trials [38]. ASAS20 and ASAS40 are among these
composite criteria, which have been validated
in previous studies of TNF blockers and are
widely used in AS clinical trials [39]. In the
current network meta-analysis of biologic
treatments for active AS, infliximab had the
lowest NNT to achieve an additional ASAS20/40
response, and adalimumab had the lowest
12-week cost per ASAS20/40 responder.
Previous research has assessed the efficacy of
different biologic agents in the treatment of AS
using conventional pairwise meta-analyses. One
study compared adalimumab, etanercept, and
infliximab with placebo, and found that these
TNF inhibitors had significantly better efficacy
than placebo, in terms of pain, physical
function, patient’s global assessment, and
acute phase reactants [40]. Other more recent
studies assessed the efficacy of TNF blockers as a
class by pooling studies of different agents
together (adalimumab, certolizumab pegol,
etanercept, golimumab, and infliximab)
[3, 14, 41]. In those studies, TNF inhibitors
showed better efficacy than placebo for BASDAI,
Bath Ankylosing Spondylitis Functional Index
(BASFI), Bath Ankylosing Spondylitis Metrology
Index (BASMI), ASAS20, ASAS40, ASAS50, and
ASAS70 response among patients with AS. One
previous indirect comparison study assessed the
relative efficacies among adalimumab,
etanercept, golimumab, and infliximab [42].
However, that study only evaluated ASAS20
and did not include the newer biologic agents
(certolizumab pegol and secukinumab);
moreover, it did not take drug cost into
consideration in the comparisons. A recent
report by the National Institute for Health and
Table 2 Number needed to treat and cost per ASAS20 responder






Placebo 27.9% (25.3%, 30.6%) – – –
Adalimumab 63.6% (53.2%, 72.5%) 4.5 (3.0, 6.7) 2.8 (2.3, 3.9) $26,888 ($21,720, $37,320)
Certolizumab pegola 50.5% (32.9%, 68.4%) 2.6 (1.3, 5.5) 4.4 (2.5, 17.0) $60,326 ($33,593, $232,542)
Etanerceptb 62.0% (52.3%, 71.1%) 4.2 (2.9, 6.2) 2.9 (2.3, 4.0) $28,199 ($22,483, $38,633)
Golimumab 60.2% (47.4%, 71.8%) 3.9 (2.4, 6.5) 3.1 (2.3, 5.0) $30,417 ($22,550, $49,510)
Inﬂiximabc 71.7% (59.5%, 82.0%) 6.6 (3.9, 11.6) 2.3 (1.9, 3.1) $28,175 ($22,903, $38,694)
Secukinumab
(without loading)d
60.3% (48.1%, 71.8%) 4.0 (2.3, 6.6) 3.1 (2.3, 5.1) $33,847 ($25,149, $53,293)
Secukinumab (with loading)d 60.3% (48.1%, 71.8%) 4.0 (2.3, 6.6) 3.1 (2.3, 5.1) $67,694 ($50,299, $106,586)
ASAS20 assessment in ankylosing spondylitis 20% response, CrI credible interval, NNT number needed to treat, OR odds
ratio
Efﬁcacies were estimated based on a random effects network meta-analysis using a binomial model
a Certolizumab pegol 200 mg every 2 weeks and 400 mg every 4 weeks were treated as equivalent therapeutic doses
b Etanercept 25 mg twice a week and 50 mg every week were treated as equivalent therapeutic doses
c Drug cost of inﬂiximab was based on an 80 kg adult
d Assumes that the efﬁcacy of secukinumab 150 mg was equivalent with and without a loading dose
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Care Excellence (NICE) assessed data from
sixteen randomized clinical trials via a
network meta-analysis and compared the
efficacy of adalimumab, certolizumab pegol,
etanercept, golimumab, and infliximab in the
treatment of AS [43]. The results in the NICE
report are in line with the ones presented in this
study, in terms of both ASAS20 and ASAS40
(that report did not include data regarding the
newer agent secukinumab). The current
analyses are the first to compare the efficacy
and cost-effectiveness among a comprehensive
list of novel biologic agents for active AS
treatment. This study indicated that
adalimumab had the lowest overall cost per
responder in the treatment of active AS (when
considering both ASAS20 and ASAS40
response), which is consistent with previous
studies regarding the cost per responder
associated with biologic therapies for Crohn’s
disease, psoriasis, and rheumatoid arthritis
[44, 45].
The recently published 2015 American
College of Rheumatology (ACR)/Spondylitis
Association of America (SAA)/Spondyloarthritis
Research and Treatment Network (SPARTAN)
guidelines for the treatment of AS recommend
TNF inhibitors in adults with AS when activity
persists despite treatment with NSAIDs [46]. The
guidelines do not recommend a particular TNF
inhibitor, except in patients with AS and
inflammatory bowel disease where treatment
with TNF inhibitory monoclonal antibodies
(such as adalimumab or infliximab) is
preferred over etanercept. While the guidelines
do not include secukinumab, the FDA suggested
cautious use of secukinumab in patients with
inflammatory bowel disease due to
exacerbations observed during the clinical
trials [8].
Table 3 Number needed to treat and cost per ASAS40 responder






Placebo 13.5% (11.4%, 15.9%) – – –
Adalimumab 49.2% (36.0%, 63.4%) 6.2 (3.8, 10.8) 2.8 (2.0, 4.3) $26,898 ($19,483, $41,699)
Certolizumab pegola 34.8% (18.8%, 56.2%) 3.4 (1.5, 8.1) 4.7 (2.3, 16.6) $64,051 ($31,815, $227,020)
Etanerceptb 41.4% (25.6%, 60.1%) 4.6 (2.3, 9.3) 3.6 (2.2, 8.0) $34,406 ($20,866, $76,436)
Golimumab 38.6% (24.5%, 55.5%) 4.0 (2.2, 7.8) 4.0 (2.4, 8.5) $39,030 ($23,760, $83,570)
Inﬂiximabc 51.5% (33.4%, 70.0%) 6.8 (3.3, 14.8) 2.6 (1.8, 4.9) $32,508 ($21,954, $60,308)
Secukinumab (without
loading)d
42.4% (28.1%, 59.2%) 4.7 (2.6, 9.1) 3.5 (2.2, 6.6) $37,850 ($24,274, $72,096)
Secukinumab (with loading)d 42.4% (28.1%, 59.2%) 4.7 (2.6, 9.1) 3.5 (2.2, 6.6) $75,701 ($48,547, $144,191)
ASAS40 assessment in ankylosing spondylitis 40% response, CrI credible interval, NNT number needed to treat, OR odds
ratio
Efﬁcacies were estimated based on a random effects network meta-analysis using a binomial model
a Certolizumab pegol 200 mg every 2 weeks and 400 mg every 4 weeks were treated as equivalent therapeutic doses
b Etanercept 25 mg twice a week and 50 mg every week were treated as equivalent therapeutic doses
c Drug cost of inﬂiximab was based on an 80 kg adult
d Assumes that the efﬁcacy of secukinumab 150 mg was equivalent with and without a loading dose
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As in other indirect comparison studies, this
network meta-analysis also has some
limitations. Given the small numbers of
eligible trials for each pairwise comparison in
the network, appropriate adjustment of baseline
risks for each trial was rendered impossible. In
addition, although the network meta-analysis
synthesizes results from randomized clinical
trials, the comparative efficacy was mostly
based on indirect evidence, and may be
influenced by potentially observed or
unobserved differences across the trials.
However, this network meta-analysis
represents the best evidence available for the
comparative efficacy of biologic treatment for
active AS, and this information is crucial for
health technology assessment and other
decision-making in this field. In addition, this
study included one open-label trial with limited
sample size comparing etanercept with
infliximab [29]. The responses reported in this
trial, however, are similar to the results from the
current network meta-analysis. Therefore,
including this study will not significantly
affect the estimates in this study and may in
fact strengthen the analysis by directly linking
two of the biologic agents.
Most of the AS clinical trials included in this
analysis allowed concomitant use of DMARDs
(e.g., sulfasalazine, methotrexate) and
corticosteroids; however, the cost per
responder analyses include only the biologic
drug costs (and associated administration cost).
This study did not consider direct medical costs
associated with treatment, such as those
associated with hospitalization and
rheumatology visits. Moreover, this analysis
did not compare safety and tolerability
outcomes, and thus, did not include
subsequent costs associated with potential
adverse events. Nonetheless, most of the
biologic agents did not show significantly
different rates of serious adverse events
compared with placebo (except for
certolizumab pegol) in a Cochran
meta-analysis of clinical trials data [47], and
rates of concomitant use of DMARDs and
corticosteroids were similar across trials so the
inclusion of these outcomes and associated
costs would be unlikely to alter the
conclusions of this study. To be consistent
with the primary endpoints of AS clinical
trials, this study only considers 12-week costs
for all treatments and does not speculate on the
cost-effectiveness over longer periods of
treatment. Future economic modeling studies
may be helpful in understanding the full picture
of healthcare costs associated with biologic
treatments of AS. Lastly, the lack of
certolizumab pegol trial results stratified by
previous TNF inhibitor exposure limited the
ability to conduct the analysis in a pure
TNF-naı¨ve population. As the proportion of
patients with prior TNF exposure is relatively
small and the exposure would affect both the
placebo and the active agent, the results are
unlikely to be markedly affected by the
inclusion of TNF-experienced patients for
certolizumab pegol and secukinumab.
CONCLUSIONS
The current analyses are the first to compare
the efficacy and cost-effectiveness among all
available biologic agents for the treatment of
active AS. In these analyses, adalimumab and
infliximab demonstrated higher efficacy and
lower cost per responder in terms of both
ASAS20 and ASAS40. The study results
indicate the potential for these agents to be
used more cost-effectively in the treatment of
active AS.
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